Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Simon Vanveggel"'
Autor:
Eduardo Arathoon, Asad Bhorat, Rodica Silaghi, Herta Crauwels, Ludo Lavreys, Lotke Tambuyzer, Ben Van Baelen, Simon Vanveggel, Magda Opsomer
Publikováno v:
SAGE Open Medicine, Vol 5 (2017)
Objective: VIOLIN (TMC125IFD3002; NCT01422330) evaluated the safety, tolerability, and pharmacokinetics of etravirine with antiretrovirals other than darunavir/ritonavir in HIV-1-infected patients. Methods: In a 48-week, phase IV, single-arm, multice
Externí odkaz:
https://doaj.org/article/1d2fcd3a30fa484aba5a23fc61ee58a6
Autor:
Thomas A. Lutz, Susan Swindells, Vasiliki Chounta, Christine L. Talarico, Jenny Huang, Lelanie van Zyl, Paul D Benn, William Spreen, Kati Vandermeulen, Kimberly Y. Smith, Herta Crauwels, Conn M. Harrington, Essack Mitha, Norma Porteiro, Susan L. Ford, Simon Vanveggel, Matthias Stoll, Kai S Hove, Rodica Van Solingen-Ristea, David A. Margolis, Alyssa Shon
Publikováno v:
AIDS (London, England)
Background: ATLAS (NCT02951052), a phase 3, multicenter, open-label study, demonstrated that switching to injectable cabotegravir (CAB) with rilpivirine (RPV) long-acting dosed every 4 weeks was noninferior at week (W) 48 to continuing three-drug dai
Autor:
Simon Vanveggel, Kimberly Y. Smith, David A. Margolis, Krischan J Hudson, Paul D Benn, Mark S. Shaefer, Anthony Mills, Yuanyuan Wang, Rodica Van Solingen-Ristea, Susan Swindells, William Spreen, Edgar T. Overton, Vasiliki Chounta
Publikováno v:
The Patient
Background Advances in HIV-1 therapeutics have led to the development of a range of daily oral treatment regimens, which share similar high efficacy rates. Consequently, more emphasis is being placed upon the individual’s experience of treatment an
Autor:
Veerle Van Eygen, David A. Margolis, Marty St. Clair, Jerry Jeffrey, Daniel R. Kuritzkes, Michael Aboud, Jan van Lunzen, Yongwei Wang, William Spreen, Christine L. Talarico, Mark Baker, Kati Vandermeulen, Amy Cutrell, Carlo Federico Perno, Jonathan M. Schapiro, David Dorey, Susan L. Ford, Herta Crauwels, C. Thomas White, Joseph W. Polli, Romina Quercia, Simon Vanveggel, Sterling Wu, Parul Patel
Publikováno v:
AIDS (London, England)
Current antiretroviral therapy (ART) consists of a combination of two or more oral agents from at least two drug classes, such as an integrase strand transfer inhibitor (INSTI) as well as one or two nucleoside reverse transcriptase inhibitors (NRTIs)
Autor:
Miguel García Deltoro, Veerle Van Eygen, Paul D Benn, Kimberly Y. Smith, Hans Jaeger, Parul Patel, Fritz Bredeek, Rodica Van Solingen-Ristea, Christine L. Talarico, William Spreen, Marie-Aude Khuong-Josses, Simon Vanveggel, Susan L. Ford, Gary Richmond, Edgar T. Overton, Giuliano Rizzardini, Krischan J Hudson, Amy Cutrell, Susan Swindells, Vasiliki Chounta, Jaime Andrade-Villanueva, Catherine Orrell, Herta Crauwels, David A. Margolis, Mark S. Shaefer, Firaya Nagimova, Yuanyuan Wang, Alexander Wong
Publikováno v:
The Lancet. 396:1994-2005
Phase 3 clinical studies showed non-inferiority of long-acting intramuscular cabotegravir and rilpivirine dosed every 4 weeks to oral antiretroviral therapy. Important phase 2 results of every 8 weeks dosing, and supportive modelling, underpin furthe
Autor:
Luminita Ene, Natalia Zakharova, Rodica Van Solingen-Ristea, Veerle Van Eygen, Pedro Cahn, Eric Van Wijngaerden, Simon Vanveggel, Gerd Fätkenheuer, Johan Lombaard, Jean-Michel Molina
Publikováno v:
Antiviral therapy. 26(6-8)
Background To evaluate the long-term safety and efficacy of rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), in combination with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) in human immunodeficiency viru
Autor:
Miranda Murray, David Dorey, Simon Vanveggel, Enrique Bernal, Anthony Mills, Jenny Huang, Sharon Walmsley, David A. Margolis, Hans Jäger, Mark S. Shaefer, Vasiliki Chounta, Marie-Aude Khuong-Josses, Krischan J Hudson, Sandy Griffith, William Spreen, Harold P. Katner, Antonio Antela, Johan Lombaard
Publikováno v:
AIDS and Behavior
The phase 3 ATLAS and FLAIR studies demonstrated that maintenance with Long-Acting (LA) intramuscular cabotegravir and rilpivirine is non-inferior in efficacy to current antiretroviral (CAR) oral therapy. Both studies utilized Patient-Reported Outcom
Autor:
David A. Margolis, Conn M. Harrington, Krischan J Hudson, Christine L. Talarico, Pedro Cahn, Simon Vanveggel, Fritz Bredeek, Gary Richmond, Wim Louis Julien Parys, Jenny Huang, Giuliano Rizzardini, Herta Crauwels, Vadim Pokrovsky, Parul Patel, Peter Williams, Joseph M. Mrus, Jaime-Federico Andrade-Villanueva, Graham H R Smith, Susan Swindells, Susan L. Ford, Yeon Sook Kim, Gulam H Latiff, Kimberly Y. Smith, Axel Baumgarten, Mar Masiá, Vasiliki Chounta, William Spreen
Publikováno v:
New England Journal of Medicine. 382:1112-1123
Background Simplified regimens for the treatment of human immunodeficiency virus type 1 (HIV-1) infection may increase patient satisfaction and facilitate adherence. Methods In this phase ...
Autor:
Johan Lombaard, Francis Ssali, Puthanakit Thanyawee, Jan Fourie, Simon Vanveggel, Cornelia Linthicum, Veerle Van Eygen, Rodica Van Solingen-Ristea
Publikováno v:
Antimicrobial agents and chemotherapy. 66(2)
This phase 2 study investigated long-term safety and efficacy of rilpivirine (RPV [Edurant]) plus two investigator-selected nucleos(t)ide reverse transcriptase inhibitors (NRTIs) in HIV-1-infected antiviral therapy-naive adolescents. Participants (
Autor:
Jaime Andrade-Villanueva, Yuanyuan Wang, Christine L. Talarico, David A. Margolis, Anders Thalme, Veerle Van Eygen, Gary Richmond, Susan L. Ford, Kimberly Y. Smith, Elena Belonosova, Rodica Van Solingen-Ristea, Giuliano Rizzardini, Antonio Ocampo Hermida, Rosie Mngqibisa, Paul D Benn, Herta Crauwels, Krischan J Hudson, Hans Jaeger, William Spreen, Faiza Ajana, Edgar T. Overton, Carlos Martin Espanol, Simon Vanveggel
Publikováno v:
The lancet. HIV. 8(11)
Summary Background Long-acting cabotegravir and rilpivirine administered monthly or every 2 months might address the challenges associated with daily oral antiretroviral therapy. The ATLAS-2M week 48 results showed non-inferiority of long-acting cabo